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A HIV-1 Nef affinity column was used to purify a 35-
kDa Nef-interacting protein from T-cell lysates. The 35-
kDa protein was identified by peptide microsequence
analysis as the human thioesterase II (hTE) enzyme, an
enzyme previously identified in a yeast two-hybrid
screen as a potential Nef-interacting protein. Immuno-
fluorescence studies showed that hTE localizes to per-
oxisomes and that coexpression of Nef and hTE leads to
relocalization of Nef to peroxisomes. Interaction of Nef
and hTE was abolished by point mutations in Nef at
residues Asp108, Leu112, Phe121, Pro122, and Asp123. All of
these mutations also abrogated the ability of Nef to
down-regulate CD4 from the surface of HIV-infected
cells. Based on the x-ray and NMR structures of Nef,
these residues define a surface on Nef critical for CD4
down-regulation. A subset of these mutations also af-
fected the ability of Nef to down-regulate major histo-
compatibility complex class I. These results, taken to-
gether with previous studies, identify a region on Nef
critical for most of its known functions. However, not all
Nef alleles bind to hTE with high affinity, so the role of
hTE during HIV infection remains uncertain.
The nef gene of the human immunodeficiency virus (HIV)1
encodes a 27-kDa myristoylated cytosolic protein that associ-
ates with the plasma membrane and other intracellular vesicle
surfaces (1–3). Although the precise functions of Nef remain
controversial, in SIV-infected adult macaques Nef expression is
critical for the maintenance of a high viral load and progression
to AIDS (4). Moreover, in humans, several long term survivors
of HIV infection carry HIV with deletions in nef or with a high
frequency of defective nef alleles (5–7).
How Nef achieves these in vivo effects is not yet clear. How-
ever, in tissue culture a number of effects of Nef have been
documented. First, it enhances viral infectivity and replication
in primary cells (8, 9). Second, it alters the state of T-cell
activation and macrophage signal transduction pathways (10–
13). Third, it reduces the cell surface expression of CD4, one of
the cellular receptors for HIV (1–3, 14). The internalization and
degradation of cell surface CD4 by Nef increases the infectivity
of the released virion particles because CD4 interferes with
incorporation of the HIV envelope protein into the virus parti-
cle (15, 16). Finally, Nef also down-regulates cell surface ex-
pression of MHC class I. This effect may be important for HIV
immune evasion (17–20). Because Nef has no known catalytic
activity, the above activities are probably mediated through
interaction of Nef with host cell proteins, and several cellular
proteins have been suggested to interact with Nef. For exam-
ple, Nef contains a consensus SH3 domain binding sequence
(PXXP) that mediates Nef association with members of the Src
tyrosine kinase family (21–24). Nef also associates with com-
ponents of the endocytic machinery, b-cop, and the clathrin
adaptor complex, and these interactions are important for link-
ing CD4, through Nef, to endocytic pathways (19, 25–29). Nef
has also been reported to interact with a member of the p21-
activated kinase family (30, 31) and a vacuolar ATPase (32).
Recently, another Nef-interacting protein, human thioester-
ase (hTE), was cloned from a Jurkat T-cell cDNA library in a
yeast two-hybrid screen (33, 34). hTE belongs to a novel class of
thioesterases and exhibits 42% amino acid identity with an
Escherichia coli thioesterase II (35). The precise biological
function of either hTE or its E. coli homolog is not yet clear. The
best characterized thioesterases are involved in lipid metabo-
lism; yet overexpression or deletion of the bacterial TEII en-
zyme in E. coli had no detectable effect on fatty acids levels
(35).
To investigate the role of Nef in modulating cell-signaling
pathways, we used a Nef affinity column to purify Nef-inter-
acting proteins from T-cell lysates. We found that hTE was the
only protein in a T-cell lysate that associated with Nef with
high enough affinity to be identified by peptide microsequence
analysis in this screen. We then identified five point mutations
in Nef that abolish binding to hTE. All of these mutations
abrogated the ability of Nef to down-regulate CD4 from the
surface of infected cells. Based on the x-ray and NMR struc-
tures of Nef, these mutations defined a surface on Nef critical
for CD4 down-regulation. We found that part but not all of this
region on Nef is also critical for Nef-induced MHC class I
down-regulation. The mutagenesis analysis and in vivo immu-
nofluorescence colocalization studies with Nef and hTE suggest
that hTE plays a role during HIV infection. However, we found
that not all Nef alleles bind to hTE with high affinity (e.g. SF2
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Nef and SIV Mac239 Nef). Therefore, it is uncertain whether
hTE binding plays a critical role in Nef function.
EXPERIMENTAL PROCEDURES
Plasmid Constructions—The pGEX2T vector construct (Amersham
Pharmacia Biotech) was used to express glutathione S-transferase fu-
sion proteins of various Nef mutants. hTE cDNA containing a hexahis-
tidine tag followed by a thrombin cleavage site was cloned into the
expression vector, pRSET (Invitrogen) for expression in bacteria. Genes
encoding for CD4, various Nef alleles, green fluorescence protein (GFP)
fusion proteins, and N-terminally Flu-tagged hTE were cloned into the
pBABE retroviral expression vector (36) for expression in mammalian
cells. Nef-GFP fusion constructs contained Nef at the 59 end, a 12-base
pair linker (GGC GGC CGC AGC) and enhanced humanized GFP
(CLONTECH) at the 39 end and are similar to a previously described
construct used in Nef localization studies (28).
Random Mutagenesis of Nef at Residues Leu76, Pro78, Asp108, Leu112,
Tyr115, Phe121, Pro122, and Asp123—For each residue mutated we syn-
thesized a pair of overlapping primers where the codon to be mutated
was synthesized using a mixture of all four nucleotide precursors. For
example, the coding strand primer for mutating NL4–3 Nef at Asp108
contained the sequence CAC TCC CAA AGA AGA CAA NNC ATC CTT
GAT CTG TGG ATC (where that N indicates all four nucleotide bases
were used). A separate polymerase chain reaction and ligation reaction
was then done for each of the 8 residues to create a library of mutants
at that residue. For each residue, 10 bacterial colonies were chosen at
random and tested for association with hTE in the GST pull-down
assay.
Purification of Recombinant GST Fusion and Nef Proteins—Bacteria
containing the hTE/pRSET plasmid were induced for hTE expression by
the addition of 1 mM isopropyl-1-thio-b-D-galactopyranoside for 2–6 h.
Cells were harvested, lysed by sonication, and centrifuged. The super-
natant was passed over a nickel-nitrilotriacetic acid column and
washed with a buffer containing 90 mM imidazole followed by elution of
hTE with a buffer containing 200 mM imidazole.
GST fusion proteins from bacteria were purified using glutathione-
agarose beads (Molecular Probes) (24). Nef protein alone (in the absence
of GST) was obtained by cleaving the thrombin cleavage site in the
GST-Nef fusion protein, while the fusion protein was immobilized to the
agarose beads. The eluted Nef protein was further purified by fast
protein liquid chromatography over a Mono Q column (Amersham
Pharmacia Biotech) followed by dialysis. This purified Nef protein was
used to make a Nef affinity column using Affi-Gel beads (Bio-Rad) and
for other experiments (e.g. circular dichroism) described in the text.
Purification of Nef-interacting Proteins from T-cell Lysates—Fresh
calf thymii were washed in ice-cold PBS, cut into small pieces, and 2
volumes (weight to volume) of ice-cold buffer A (10% glycerol, 25 mM
Hepes, pH 7.5, 140 mM KCl, 1.3 mM EDTA, 1.0 mM MgCl2, 3.0 mM
dithiothreitol) plus 0.01% aprotinin, 0.1 mg/ml phenylmethylsulfonyl
fluoride, 1 mM KF, 0.25 mM orthovanadate, and 1 mM leupeptin were
added. This mixture was pureed in a blender and sieved through a
metal basket. Triton X-100 was added to 0.25%, and the mixture was
stirred for 209 at 4 °C and centrifuged 159 at 1,500 3 g, and the
supernatant was passed through cheese cloth, recentrifuged at
20,000 3 g for 459, and then recentrifuged again at 80,000 3 g. The
supernatant was adjusted to 0.02% azide, held at 4 °C overnight, and
respun at 80,000 3 g. The supernatant was then precleared by passing
over an Affi-Gel bead column. Affi-Gel beads containing cross-linked
Nef were then added (final concentration of Nef varied between 0.1 and
1.0 mM), and the mixture was rotated overnight at 4 °C. The beads were
then transferred to a column, and washes were done with Buffer A plus
increasing concentrations of NaCl (up to 1.0 M). Nef-associated proteins
were eluted in Buffer A plus 2.0 M NaCl, concentrated by acetone
precipitation, and analyzed by SDS-PAGE, and the proteins were trans-
ferred to a polyvinylidene difluoride membrane for peptide microse-
quence analysis.
Determination of Enzyme Activity of hTE—The enzyme activity of
hTE was measured spectrophotometrically using Ellman’s reagent
(5,59-dithiobis(2-nitrobenzoic acid)) as described (37, 38) with 0.125 mg
of purified hTE in a volume of 0.25 ml. An hTE radiochemical assay (37,
38) contained [1-14C]palmitoyl CoA (31.4 Ci/mol) in a volume of 0.1 ml
and incubations at 25 °C. The free 14C palmitic acid produced was
extracted and assayed by liquid scintillation spectrometry.
Glutathione-Agarose Pull-down Assay—Extracts from 1.5 ml of bac-
teria culture expressing GST-Nef fusion proteins were prepared by
sonication in 1 ml of PBS, 50 mM EDTA, 10% glycerol, 1% Triton X-100,
1% aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithio-
threitol. Purified hTE (50–100 mg) was added to these crude bacterial
lysates along with 10–20 ml of glutathione-agarose beads. Binding was
carried out at 4 °C for 1 h. The beads were spun down and washed with
the binding buffer containing 0.1% Triton X-100 and 1 mM EDTA.
Bound proteins were eluted by boiling in SDS-PAGE sample buffer and
analyzed by SDS-PAGE/Coomassie Blue staining of the gel.
Cell Lines, HIV Preparation, and Flow Cytofluorimetry Analysis—
The human lymphoblastoid cell line 721.221 expressing CD4 and
HLA-A2 (17) and Bosc cells (39) are as described. Human embryonic
kidney 293 cells and Bosc cells were transfected with various DNAs by
the calcium phosphate precipitation method (39).
HIV was generated from transfected 293 cells and HIV infection of
target cells was done as described (40). Wild-type and various Nef
mutants were cloned into the NL-PI vector derived from the molecular
clone NL4–3 that carries the full complement of HIV genes as well as
encoding for the placental alkaline phosphatase (PLAP) reporter gene
(40). Single-round infectivity assays were performed using CD4-positive
HeLa cells containing an HIV-LTR-bGal reporter (MAGI cells) (41).
Jurkat T-cells and CD4 positive 721.221 cells expressing HLA-A2
were infected with HIV-1 reporter virions encoding for PLAP. 2 days
post-infection, the cells were stained for CD4, MHC class I, or PLAP
expression followed by cytofluorimetry on a Becton Dickinson FACS-
CAN as described (17, 40). Down-regulation of CD4 in 293 cells was
monitored after cotransfection of plasmids encoding for CD4 and vari-
ous Nef mutants into 293 cells. CD4 expression levels were measured 2
days post-transfection by FACS. Nef expression levels were monitored
by Western blot analysis.
Immunofluorescence Microscopy—Nonreplication competent murine
ecotropic retroviruses carrying the Nef-GFP fusion gene or Flu-tagged
hTE were made using the retrovirus packaging cell line Bosc (39).
Nef-GFP and Flu-hTE retroviruses were used either alone or together
to (co)infect mouse NIH-3T3 cells. Infected 3T3 cells were grown on
coverslips and stained 2 days post-infection. Cells were fixed in
paraformaldehyde/PBS, washed in PBS buffer, quenched in 50 mM
NH4Cl/PBS, and permeabilized in PBS containing 0.1% Triton X-100
and 1 mg/ml BSA. Cells were incubated with anti-Flu tag antibodies,
washed three times, and stained with a Texas Red-conjugated second-
ary antibody. After three washes in PBS, cells were mounted on micro-
scope slides in 100 mM Tris-HCl, pH 8.5, 100 mg/ml Mowiol, 25 mg/ml
1,4-diazabicyclo[2.2.2.]octane, and 25% glycerol and examined under a
epifluorescence microscope attached to a CCD camera or to a confocal
microscope. No immunofluorescence staining was observed when sec-
ondary antibodies were used without the primary antibody or with an
irrelevant primary antibody.
RESULTS
Nef Associates with a Human Thioesterase—When cell ly-
sates from human Jurkat T-cells were applied to a GST-Nef
affinity column (NL4–3 Nef allele), a 35-kDa protein bound to
the column, but it did not bind to a control column containing
the GST protein alone (data not shown). Because certain func-
tions of HIV-Nef such as CD4 down-regulation can be species-
independent (13, 42), we tested whether a 35-kDa protein
might also be found in a T-cell extract derived from calf thy-
mus. For this experiment we used an affinity column of Nef
alone covalently attached to Affi-Gel beads. Once again, only a
35-kDa protein was seen to specifically associate with the Nef
affinity column but not with the control column (Fig. 1A, lanes
1 and 3). The protein seen at 27 kDa in lane 1 is Nef that was
noncovalently attached to the column and came off when the
beads alone, which had not been exposed to thymus extract,
were boiled in SDS loading buffer (Fig. 1A, lanes 4 and 5).
Similarly, the proteins seen at 55 kDa in lane 1 were not
derived from the T-cell extract because they were present when
the beads alone were boiled in loading buffer (Fig. 1A, lanes 4
and 5), and they most likely represent dimerized Nef or resid-
ual GST-Nef from which the Nef was derived. The association
of the 35-kDa protein (p35) with Nef was independent of the
presence of the PxxP motif in Nef because a mutant Nef lacking
the motif (P72A, P75A) (24), still bound to p35 (Fig. 1A, lane 2).
Therefore, the 35-kDa protein probably is not binding to Nef
through a SH3 domain interaction.
hTE Binding Site on Nef23098
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Decem
ber 29, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
The 35-kDa protein was purified from the calf thymus ex-
tract and subjected to peptide microsequence analysis. All
seven peptide sequences obtained by peptide microsequence
analysis (data not shown) were found in a single human ex-
pressed sequence tag data base clone. Using this information,
we cloned the cDNA for a protein that is 42% identical to a
bacterial protein called thioesterase II. This protein termed
hTE was overexpressed in E. coli with a histidine tag at the N
terminus of the protein. That the recombinant hTE and Nef
could interact directly was then demonstrated in vitro. Purified
His-tagged hTE or His-tagged HIV matrix protein (a control
protein) were incubated with a bacterial cell lysate from cells
expressing either GST-Nef or GST. Proteins present in the
glutathione-agarose bound fraction were separated by SDS-
PAGE. As shown in the Fig. 1B, GST-Nef was able to bind hTE
(lane 4) but not the HIV matrix protein (lane 3), whereas GST
alone was unable to bind hTE (lane 2) or the HIV matrix
protein (lane 1). Based on the intensity of staining with Coo-
massie blue, Nef and hTE appear to interact in an approxi-
mately stoichiometric ratio.
We also investigated whether Nef can interact with the E.
coli TE II homolog or rat mammary gland thioesterase II (43)
(rat TEII belongs to a class of thioesterases that do not share a
sequence similarity to hTE). However, we found that neither of
these thioesterases could interact with HIV Nef in the GST
pull-down assay (data not shown). Therefore, the amino acid
residues in hTE that are not conserved in the E. coli homolog
are important in the interaction with HIV Nef.
Enzymatic Properties of hTE—The homolog of hTE from E.
coli hydrolyzes acyl-CoAs of various chain lengths (35). There-
fore, hTE was assessed for its ability to utilize various acyl-
CoAs as substrates. Enzyme activity of hTE was measured
either by a spectrophotometric assay or a radiochemical assay
(37, 38). The hTE protein hydrolyzed acyl-CoA substrates of
chain lengths C8, C10, C12, C14, and C16. The Vmax values for
these substrates are 9, 6, 5, 8, and 8 mmol/min/mg respectively.
The turnover number (kcat) of hTE with C10-CoA as a substrate
is about 12-fold lower than that of E. coli thioesterase II. The
pH optimum for the enzyme was between pH 8.0 and 8.2,
similar to that of the E. coli enzyme. Kinetic analysis of the
enzyme revealed that hTE, like its E. coli counterpart, works
on a broad range of acyl chain length acyl-CoAs, but Km values
tend to increase with decreasing chain length. The Km value for
C8, C10, C12, C14, and C16 acyl-CoA substrates is 82, 20, 4, 4,
and 2 mM, respectively. Therefore, the specificity of the enzyme,
as measured by Vmax/Km, shows a preference for longer chain
fatty acids. Incubation of the purified hTE with a 7-fold excess
of GST-Nef, conditions known to favor the hTE-Nef interaction,
had no effect on the enzyme activity either under substrate-
limiting (s , Km) or saturating (s . Km) conditions when
assayed using decanoyl-CoA as a substrate (data not shown).
Analysis of Subunit Structure of hTE—Earlier studies had
indicated that E. coli thioesterase II exists as a tetramer (35).
Therefore, the subunit structure of hTE was investigated by gel
filtration high pressure liquid chromatography using a Sig-
machrom GFC-1300 (300 3 7.5 mm) column. We found that the
oligomeric status of hTE is highly dependent on protein con-
centration. At 3 mg/ml hTE ran as a tetramer on a gel filtration
column with no sign of any material corresponding to either a
dimer or monomer of hTE. However, upon dilution to 0.5 mg/
ml, hTE ran as a dimer. Both the tetrameric and dimeric forms
of hTE exhibited similar enzymatic activity (data not shown).
The hTE protein contains eight cysteine residues. However,
because b-mercaptoethanol treated and untreated hTE both
ran as a single band corresponding to a molecular mass of 35
kDa when subjected to SDS-PAGE, it is unlikely that disulfide
bridges contribute to the polymerization of the protein (data
not shown).
Identification of hTE Binding Site on Nef—A previous report
of Nef interaction with hTE identified a mutant, called Mut.4,
that did not interact with hTE (33). This Nef mutant contains
5 point mutations from the original Nef-LAI wild-type se-
quence: W57R, F68S, D123G, H166R, and L170Q. To identify
residue(s) that are critical for interaction with hTE, we mu-
tated the above residues in Nef allele NL4–3 individually and
tested the resulting mutant Nef proteins for their ability to
interact with hTE in a Gst-Nef pull-down assay (Fig. 1C).
Except for the Nef protein carrying the mutation, D123G, all
the other single Nef mutants exhibited normal interaction with
hTE. We also did not detect an interaction between D123G Nef
and hTE in a yeast two-hybrid screen (data not shown). Be-
cause wild-type and D123G Nef show similar CD spectra, tem-
FIG. 1. A, a 35-kDa protein specifically interacts with HIV NL4–3
Nef. Calf thymus extract was applied to an affinity column containing
wild-type Nef-AffiGel (lane 1), P72A 1 P75A mutant Nef-AffiGel (lane
2), or AffiGel column alone (lane 3). After extensive washing, the gel
material was boiled in SDS loading buffer, proteins bound to the column
were separated by SDS-PAGE, and the gel was stained with Coomassie
Brilliant Blue. Lanes 4–6 are beads corresponding to lanes 1–3, respec-
tively, except that these beads were never exposed to calf thymus
extract. B, association of Nef with hTE in vitro. Purified hTE (lanes 2
and 4) or HIV matrix protein (lanes 1 and 3) were incubated with
lysates from bacterial cells expressing either GST (lanes 1 and 2) or
Nef-GST fusion protein (lanes 3 and 4) in the presence of glutathione-
agarose beads. After extensive washing, proteins bound to the gluta-
thione-agarose beads were separated by SDS-PAGE, and the gel was
stained with Coomassie Brilliant Blue. C, ability of various Nef mu-
tants to interact with hTE in vitro. Purified hTE was either absent or
added to lysates from bacterial cells expressing GST fusions of various
Nef mutants in the presence of glutathione-agarose beads (the absence
or presence of added hTE is indicated as 2 or 1 in the hTE row above
the gel). Bound proteins were analyzed by SDS-PAGE, and the gels
were stained with Coomassie Brilliant Blue. The ability of the 35-kDa
hTE to bind to the Nef mutant is indicated by the presence of an
additional band at 35 kDa in the lane that contains added hTE (hTE 1).
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perature melt CD curves, and the ability to interact with the
Hck SH3 domain in a GST pull-down assay (data not shown),
these results suggest that this mutation does not cause a global
disruption in Nef structure. Moreover, in vivo the D123G Nef
mutant retains some of its Nef-associated activities (see
below).
The mutant D123G Nef and other Nef mutants were then
cloned back into HIV strain NL4–3 (NL-PI) carrying the PLAP
reporter gene. PLAP is a cell surface protein, and PLAP ex-
pression allows us to follow HIV infection of cells by flow
cytometry (40). The ability of these various mutants to down-
regulate CD4 was assessed in HIV-infected Jurkat cells. NL-PI
carrying wild-type Nef alleles down-regulates CD4 rapidly in
this assay. Therefore, there appears to be a direct inverse
relation between PLAP expression and CD4 levels in Jurkat
cells (Fig. 2). However, in NL-PI carrying a frameshift in Nef,
there is little CD4 down-regulation until there are high levels
of PLAP expression. CD4 down-regulation in these cells is due
to the synthesis of two late HIV genes, Vpu and Env (40). F68S
Nef, H166R Nef, and L170Q Nef proteins that interact with
hTE were able to induce CD4 down-regulation similar to the
wild-type protein (Fig. 2 and Table I). However, neither D123G
Nef (Fig. 2) nor W57R Nef (Table I) induced CD4 down-regu-
lation either within the context of HIV infection of T-cells or in
cotransfection assays of CD4 and Nef into human 293 cells
(data not shown). The Trp57 residue has been speculated to
play a role in direct binding to CD4 (44); however, mutation of
another Nef residue, E59A, also speculated to interact with
CD4, had no effect on CD4 down-regulation (data not shown).
Although there was a small variability in the expression level
of these various mutants relative to the wild-type Nef protein
TABLE I
Ability of mutant Nef alleles to induce CD4 down-regulation
and bind to hTE
Ability of Nef alleles to down-regulate CD4 was determined either by
cotransfection of 293 cells with plasmids encoding for CD4 and various
mutant Nef alleles or by infection of Jurkat T cells with HIV-1 virions
encoding for PLAP and various mutant Nef alleles. Down-regulation of
CD4 was monitored by flow cytometry as described under “Experimen-
tal Procedures.” Association of mutant Nef alleles with hTE was fol-
lowed by GST-Nef pull-down assay as discussed under “Experimental
Procedures.” The amino acid numbering for SF2 Nef is based on the
corresponding residue in NL4–3 Nef to facilitate comparisons.
Nef allele CD4 downregulation Interaction with hTE
NL4–3 wild type 1 1
F68S 1 1
R105A 1 1
R106A 1 1
H166R 1 1
L170Q 1 1
P78S 1 1
Mut.4 2 2
D123G 2 2
D108A 2 2
L112D 2 2
F121G 2 2
P122R 2 2
D123V 2 2
L76P 2 1
W57R 2 1
E59A 1 1
D108E 1 2
SF2 wild type 1 2
E108D 1 1
E108A 1 Not determined
D123A 2 Not determined
SIV Mac239 1 2
FIG. 2. Flow cytometric analysis of
the ability of Nef mutants to induce
CD4 down-regulation. Wild-type and
various Nef mutants were cloned into the
NL-PI vector derived from the HIV molec-
ular clone NL4–3 that carries the PLAP
reporter gene. Human Jurkat T-cells
were infected with HIV-1 reporter virions
and 2 days later were stained for CD4 (y
axis) and PLAP (x axis).
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(at most 2-fold), we saw no correlation between the expression
level of the Nef mutants and their ability to down-regulate
CD4.
In the NMR and crystal structures of Nef (44–46), Asp123
lies in close proximity to Pro72 and Pro75 of the SH3 binding
PXXP motif (Fig. 3). Mutation of Pro72 and Pro75 affected viral
infectivity and MHC class I down-regulation but did not sig-
nificantly affect CD4 down-regulation (23, 24, 47, 48) or inter-
action with hTE (Fig. 1). To further characterize this region, we
made additional mutations and assessed the mutants for their
ability to down-regulate CD4. Because we were concerned that
mutations in this region might destabilize Nef, to maximize our
chances of obtaining stable Nef mutants we choose eight resi-
dues that cluster next to Asp123 in the crystal structure of Nef
(Fig. 3; Leu76, Pro78, Asp108, Leu112, Tyr115, Phe121, Pro122, and
Asp123), and for each of these residues, we individually ran-
domized the codon for that residue and cloned the mutant
library into the pGEX2T vector. Ten bacterial colonies were
then isolated for each residue mutated and tested for their
ability to interact with hTE in the GST pull-down assay. Anal-
ysis of these mutants told a consistent story. Mutation of Leu76
and Pro78 (and also R105A and R106A) had little effect on hTE
binding, whereas mutations at Asp108, Leu112, Phe121, Pro122,
and Asp123 abrogated Nef association with hTE (Fig. 4). Muta-
tions at Tyr115 tended to destabilize the protein as judged by
protein expression levels. Thirty-two of these mutations were
then sequenced, and although the mutagenesis was not en-
tirely random, it had introduced variability at each residue
(Fig. 4).
Of the above 80 Nef mutants we chose representatives that
appeared to be stable, based on expression levels in E. coli, and
cloned them into the HIV NL-PI vector and tested them for
their ability to induce CD4 down-regulation. Mutations that
abolished the interaction with hTE abrogated Nef-induced CD4
down-regulation, whereas mutations that did not affect hTE
binding generally had no influence on CD4 down-regulation
(Fig. 2 and Table I). Based on the structure of Nef (44–46),
residues that affect hTE binding lie together on a patch on the
surface of Nef, whereas those residues that do not affect hTE
binding lie at the periphery of this patch.
Some of these mutants were also tested for their ability to
promote MHC class I down-regulation (Fig. 5). In general, it
appears that although this region on Nef is important also for
class I down-regulation, the CD4 and class I down-regulation
regions on Nef are overlapping but distinct regions. This is in
agreement with previous reports that Pro72 and Pro75 in this
region are more important for class I down-regulation than
CD4 down-regulation (23, 24, 47, 48). The ability of some of
these mutants to down-regulate class I but not CD4 (e.g.
L112D; Fig. 5) further supports our contention that these mu-
tations do not globally disrupt Nef structure. In addition, al-
though wild-type NL4–3 virions are approximately 10-fold
more infectious in a single-cycle infectivity assay (41) than
NL4–3 virions carrying a frameshift in Nef, the Nef/hTE asso-
ciation mutants were 5-fold (D123G) to 8-fold (D108A) more
infectious than frameshifted Nef.2
Role of the N Terminus of Nef in hTE Binding—The N-
terminal region of Nef functions in both CD4 and class I down-
regulation (25, 47). However, in the NMR structure of Nef this
region was not well ordered (44, 45). Deletion analysis of Nef
suggested that this region might influence hTE binding (data
not shown). To further demonstrate the role of the Nef N
terminus in hTE binding, residues 1–35 of NL4–3 Nef were
attached to GST (GST-Nef 1–35), and its ability to associate
with hTE in the GST pull-down assay was tested. As shown in
Fig. 6A, neither hTE alone nor Nef 36–206 alone (this contains
residues 36–206 of NL4–3 Nef and is not part of a GST fusion)
interacted with GST-Nef 1–35 (lanes 4 and 5). However, when
Nef 36–206 and hTE were added together to GST-Nef 1–35,
both proteins tightly bound the N-terminal region of Nef (lane
6) but not to GST alone (lane 2). The simplest explanation of
this experiment is that either hTE binds to both the core
domain of Nef (36–206) as well as its N terminus (1–35) or that
2 G. B. Cohen, V. S. Rangan, B. K. Chen, S. Smith, and D. Baltimore,
unpublished results.
FIG. 3. Structure of Nef-SH3 com-
plex. NL4–3 Nef residues 71–130 and
SH3 domain residues 85–141 were used
to generate the space filling model of Nef-
SH3 complex according to Lee et al. (46).
hTE Binding Site on Nef 23101
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Decem
ber 29, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
the interaction of hTE with the core region of Nef increases the
avidity of the core region of Nef for the Nef N terminus. This
might suggest that upon hTE binding the N-terminal region of
Nef assumes a stable structure.
Nef Can Bind Multiple Proteins at the Same Time—Because
the SH3 binding site and hTE binding site lie in close proximity
on Nef, we tested whether Nef is able to associate with an SH3
domain and hTE at the same time. Lysates from bacteria
expressing a GST fusion with the SH3 domain from Hck (GST-
Hck-SH3) were incubated with Nef and hTE, either separately
or together, in the presence of glutathione-agarose beads. After
washing the beads were boiled in loading buffer, and bound
proteins were analyzed by SDS-PAGE. As shown in the Fig. 6B,
hTE by itself was unable to bind to the SH3 domain (lane 2),
whereas in the presence of Nef it could co-associate with the
SH3 domain (lane 4). In contrast, the D123G Nef mutant,
although it still binds to the SH3 domain (lane 5), lacks the
ability to bind hTE (lane 6). Nef could therefore function in vivo
as an adapter protein, binding multiple cell signaling proteins
at the same time.
HIV Nef Proteins Differ in Their Affinity for hTE—The asso-
ciation of Nef with a cellular serine/threonine and enhance-
ment of viral infectivity by Nef varies with different Nef alleles
(49). Therefore, three other HIV-1 Nef alleles (LAI, SF2, and
BO Nef; BO is a primary Nef allele isolate provided by Dr.
David Ho) were tested for hTE binding using the yeast two-
hybrid and GST pull-down systems. With the exception of SF2
Nef, the two other Nef proteins bound tightly to hTE (data not
shown; see also Nef alleles that bound hTE in previous studies
(33)). Overall, NL4–3 Nef and SF2 Nef, differ by 30 amino acid
residues, and SF2 Nef does down-regulate CD4 in human cell
lines (42). To localize the residues responsible for hTE associ-
ation, the following SF2/NL4–3 chimeric proteins linked to
GST were engineered; NL4–3(1–70)/SF2(71–206), NL4–3(1–
125)/SF2(126–206), and NL4–3(1–173)/SF2(174–206) (amino
acid residue numbers refer to the corresponding residue in
NL4–3 Nef) and tested for their ability to interact with hTE.
Only NL4–3(1–70)/SF2(71–206) did not interact with hTE
(data not shown). These results indicate that the region be-
tween amino acid residues 70–125 in NL4–3 Nef are probably
required for association with hTE. Because Asp108, previously
identified in the hTE binding site of NL4–3 Nef, is a glutamic
acid in SF2 Nef, we swapped these two residues between
NL4–3 and SF2 Nef. As shown in Fig. 7, D108E NL4–3 Nef did
not associate with hTE, whereas E108D SF2 Nef showed potent
hTE binding activity (in SF2 Nef the homologous residue is
residue 112 but to simplify comparisons we use the NL4–3
numbering system here). These results indicate that in SF2
Nef, the presence of Glu instead of Asp at position 108 is
responsible for the lack of interaction with hTE. Although
many HIV B-strains (frequent in Western Europe and North
America) contain an Asp at this position and are predicted to
bind to hTE, many other strains of HIV-1 as well as HIV-2 and
SIV Nef contain the Glu and will not associate with hTE. As
predicted, the one SIV Nef allele tested, Mac239, which con-
tains a Glu at this residue, did not bind to hTE (data not
shown).
Nef Colocalizes with hTE in the Peroxisomes—Northern blot
analysis revealed that the hTE gene was expressed in all tis-
sues examined including peripheral blood leukocytes (Ref. 33
FIG. 4. Random mutagenesis of Nef at defined positions. A
random Nef mutant library at defined residues was created (see “Ex-
perimental Procedures” for details). For each residue mutated, 10 bac-
terial colonies were picked and tested in the GST pull-down assay for
hTE association. The results of this analysis are summarized in this
figure. Strong hTE binding is depicted by the height of the bar on the y
axis. Nef mutants that were poorly expressed and did not bind to hTE
are depicted by a negative height on the y axis. Of the 80 mutants
tested, 32 were sequenced to determine the residue introduced by the
random mutagenesis. For the mutants that were sequenced, the amino
acid found at that residue is indicated in the graph by the single-letter
amino acid code above the bar graph.
FIG. 5. MHC class I down-regulation by Nef mutants. Human
CD4-positive 721.221 cells that expressed HLA-A2 on the cell surface
were infected with HIV-1 NL4–3 PLAP reporter virus and 2 days later
were stained for HLA-A2 surface expression (y axis) and PLAP (x axis)
as described previously (17).
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and data not shown). We then wished to determine the subcel-
lular localization of hTE and whether Nef and hTE colocalize in
vivo. The subcellular location of Nef and hTE was studied using
Nef tagged at the C terminus with GFP and hTE tagged at the
N terminus with Flu peptide. In the cells that expressed hTE,
a highly punctate pattern of staining, indicative of an associa-
tion with an intracellular organelle, was observed (Fig. 8A).
Because hTE, but not its E. coli counterpart, contains a C-
terminal tripeptide serine-lysine-leucine (SKL) peroxisomal
targeting motif (50), these organelles seemed likely to be per-
oxisomes. Deletion of the C-terminal SKL peroxisomal signal
sequence in hTE resulted in a diffuse cellular staining pattern
(Fig. 8A). Furthermore, although GFP alone displays a diffuse
staining pattern in cells (Fig. 8B), upon addition of the SKL
signal sequence at its C-terminal end (GFP-SKL), it is targeted
to peroxisomes (51). In cells coinfected with GFP-SKL and
Flu-tagged hTE, there was a striking correspondence in the
punctate cellular staining pattern (Fig. 8C), suggesting that
hTE is predominantly a peroxisomal protein. This is in agree-
ment with a recent report that the endogenous hTE is a per-
oxisomal protein (52).
In NIH 3T3 cells infected with a retrovirus encoding the Nef
NL4–3-GFP fusion protein, we observed a rather diffuse dis-
tribution of Nef-GFP throughout the cell and a more concen-
trated fluorescence pattern at the plasma membrane and in the
perinuclear region (Fig. 8D) consistent with earlier reports (28,
48). In contrast, in many of the cells coexpressing both Nef-GFP
and hTE, Nef-GFP displayed a punctate pattern of distribution
that largely colocalized with hTE in the peroxisomes (Fig. 8, E
and F). This colocalization was seen in approximately 10–20%
of the cells that coexpressed Nef and hTE. Colocalization of Nef
to peroxisomes in the presence of hTE was abolished upon
removal of the SKL signal sequence from hTE; however, the
two proteins still appeared to colocalize in other parts of the cell
(data not shown).
Similar colocalization experiments were conducted with the
Nef alleles that we previously found do not bind to hTE in vitro.
Neither SF2 Nef-GFP (Fig. 8H) nor SIV-Mac239-Nef-GFP
(data not shown) appeared to colocalize with hTE when coex-
pressed in NIH 3T3 cells. The punctate staining seen for both
SF2 (data not shown) and SIV Mac 239 Nef-GFP (Fig. 8G)
alleles in the absence of hTE has been previously described and
results from Nef colocalization with clathrin-coated vesicles
(28). Surprisingly, we found that D123G NL4–3 Nef-GFP,
which like the wild-type NL4–3 Nef has a much diminished
affinity to localize to clathrin coated vesicles (and does not show
an obvious punctate staining pattern in the absence of hTE),
colocalized with hTE upon coinfection into NIH 3T3 cells to an
extent similar to that of the wild-type protein (Fig. 8I). This is
in marked contrast to the complete inability of D123G NL4–3
Nef to bind hTE in either the GST pull-down assay (Fig. 1C) or
yeast two-hybrid assays.2 This observation suggests that in
vivo other proteins may help bring Nef and hTE together.
Alternatively, in the Nef-GFP fusion, the N-terminal of Nef is
free and probably is myristoylated (in both of the in vitro assays
Nef is fused at its N terminus and would not be myristoylated).
Because hTE has a fatty acid binding site that it uses to bind to
substrates like palmitoyl-CoA, the myristoylated Nef N termi-
nus could bind to this site and facilitate the interaction of Nef
with hTE, in vivo, in the absence of binding to the core region
of Nef.
DISCUSSION
Characterization of hTE—Using a Nef affinity column, we
have isolated and identified from T-cell lysates a 35-kDa Nef-
interacting protein, hTE. hTE had previously been identified as
FIG. 6. A, role of the N-terminal region of Nef in hTE binding. NL4–3
Nef containing residues 36–206 and hTE were incubated with lysates
from bacteria expressing GST fusion of NL4–3 Nef carrying Nef resi-
dues 1–35 in the presence of glutathione-agarose beads. Proteins bound
to the gel material were analyzed by SDS-PAGE and stained with
Coomassie Brilliant Blue. Lane 1, GST alone; lane 2, GST in the pres-
ence of hTE and Nef 36–206 (Nef 36–206 is not a GST fusion protein);
lane 3, GST-Nef 1–35 alone; lanes 4 and 5, GST-Nef 1–35 in the
presence of Nef 36–206 and hTE, respectively; lane 6, GST-Nef 1–35 in
the presence of both hTE and Nef 36–206. B, Nef can bind multiple
proteins at the same time. Lysates from bacteria expressing a GST
fusion protein with the SH3 domain from Hck (GST-Hck-SH3) were
incubated with purified wild-type Nef, D123G Nef, or hTE in the pres-
ence of glutathione-agarose beads. Bound proteins were analyzed by
SDS-PAGE, and the gel was stained with Coomassie Brilliant Blue.
Lanes 1–6 contain GST-Hck-SH3 and additions described as follows:
lane 1, no addition; lanes 2, hTE; lane 3, wild-type Nef (not a GST fusion
Nef); lane 4, both hTE and wild-type Nef; lane 5, D123G Nef; lane 6,
both hTE and D123G Nef.
FIG. 7. HIV Nef proteins differ in their affinity for hTE. Bacte-
rial cell lysates containing either GST fusion of wild-type SF2 Nef (lanes
1 and 2), E108D SF2 Nef (lanes 3 and 4), or D108E NL43 Nef (lanes 5
and 6) were incubated either in the absence (lanes 1, 3, and 5) or
presence (lanes 2, 4, and 6) of purified hTE.
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a Nef-interacting protein in yeast two-hybrid screens that used
Nef as the bait (33, 34). hTE exhibits a similar substrate
specificity and pH profile as its E. coli homolog. Binding of Nef
to hTE had no effect on thioesterase activity. We suspect that
previous reports that Nef influences the kinetic properties of
hTE (34) or that the preferred substrate for hTE are short
chain fatty acids (33) may be due to the tendency of the longer
chain fatty acids to form micelles at relatively low concentra-
tions. These negatively charged micelles may disrupt the na-
tive conformation of hTE and complicate the kinetic analysis
(53) because we have found that palmitoyl-CoA, in concentra-
tions in excess of its Km, inhibits hTE activity.
Cellular Function of hTE—Because hTE and its E. coli coun-
terpart hydrolyze the thioesterase bond of many long chain
acyl-CoA substrates, this has led to the suggestion that it may
be involved in fatty acid oxidation and lipid metabolism. Con-
sistent with a general housekeeping role for hTE, the enzyme
has been found in all organisms and all tissues examined so far.
Our finding, and a recent report (52), that hTE localizes to
peroxisomes would seem to support this speculation. Thioes-
terases in peroxisomes are presumed to regulate the local con-
centrations of acyl-CoA species and thus the extent of b-oxida-
tion of fatty acids (54). Yet at least in bacteria, overexpression
or deletion of TEII led to no detectable change in fatty acid
levels (35). Therefore, the ability of a protein to catalyze the
hydrolysis of acyl-CoA substrates in vitro does not in itself
provide sufficient evidence to conclude that acyl-CoA is the
likely substrate.
An attractive alternative role for a thioesterase might be in
the lipid modification of proteins because palmitoylation of
proteins occurs through a thioester linkage to cysteine resi-
dues. Many cell-signaling molecules such as Ras and Src family
members, seven transmembrane receptors, and CD4 itself are
palmitoylated. However, we have not been able to detect any
catalytic activity of this enzyme to remove palmitate from
protein substrates. Furthermore, mutation of the two palmi-
toylation sites in CD4 (55) neither influenced the ability of
wild-type Nef to down-regulate CD4 nor increased the activity
of the D123G mutant toward the palmitoyl-free CD4.2
Nef/hTE Interactions—Our data show that residues 108,
112, 121, 122, and 123 in Nef are critical for binding to hTE.
Based on the structure of Nef (44–46), these residues define a
surface on Nef essential for CD4 down-regulation. This region
may also play a role in Nef dimerization, and the dimer of Nef
is speculated to be the active form of Nef in vivo.3 The hTE
binding site on Nef also lies in close proximity to the SH3
domain-binding site of Nef. However, hTE and SH3 binding do
not appear to overlap because Nef was able to bind both the
Hck SH3 domain and hTE at the same time (Fig. 6B). These
results suggest that in vivo Nef may function as an adaptor
protein linking HIV into multiple cell signaling pathways
simultaneously.
We have also demonstrated that in mouse 3T3 cells, expres-
sion of hTE promotes the relocalization of Nef to peroxisomes.
This Nef/hTE colocalization is dependent upon the presence of
C-terminal peroxisomal targeting sequence, SKL, in hTE. In
the absence of this signal, Nef and hTE colocalization occurs
predominately at the plasma membrane (data not shown).
Whether Nef has any need to be localized to peroxisomes is not
clear. When both Nef and hTE are overexpressed, hTE may
recruit Nef to peroxisomes, but when Nef is present in excess
over hTE-infected as in HIV-infected cells, Nef/hTE may colo-
calize predominantly outside of peroxisomes. In this regard, it
is interesting to note that the C-terminal sequence of hTE
(C-terminal ESKL) resembles that of a PDZ domain ligand
(C-terminal ESxV) (56). PDZ domains play a role in the clus-
tering and subcellular localization of membrane proteins and
might suggest that Nef uses the hTE PDZ-like signal to influ-
ence the localization of cellular proteins.
Our results also show that although HIV Nef alleles contain
many conserved elements they differ in a number of ways,
including the affinity for cellular proteins (e.g. hTE and a
PAK-related kinase (49)), the ability to tolerate the same mu-
tation (e.g. residue 108, Table I), and perhaps their subcellular
distribution (Fig. 8, D and G). Whether this reflects true bio-
3 R. Benarous, personal communication.
FIG. 8. Nef colocalizes with hTE in
the peroxisomes. Mouse 3T3 cells were
infected with retroviruses encoding Flu-
tagged hTE and various Nef-GFP fusion
proteins. A, wild-type hTE and hTE lack-
ing the C-terminal SKL sequence; B, coin-
fection with hTE and GFP; C, coinfection
with hTE and GFP-SKL; D, NL4–3 Nef-
GFP alone; E, coinfection with hTE and
NL4–3 Nef-GFP; F, coinfection with hTE
and NL4–3 Nef-GFP, close-up view; G,
wild-type SIVmac239Nef-GFP alone; H,
coinfection with hTE and SF2 Nef-GFP; I,
coinfection with hTE and D123G NL4–3
Nef-GFP. The distribution of Flu-tagged
hTE in cells was examined by anti-Flu
antibodies followed by fluorescent Texas
Red-conjugated secondary antibodies.
Overlay in C, E, F, H, and I represents the
images of the localization of hTE and Nef-
GFP overlaid. Overlap of red (hTE) and
green (GFP) results in yellow color.
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logical differences, perhaps reflecting the adaptation of Nef to
different cellular environments, remains to be determined.
These observations might suggest that different Nef alleles
may have evolved slightly different constellations of binding
activities much as different HIV envelope proteins use different
coreceptors to gain entrance to cells (57) or as HIV and SIV
capsid proteins differ in their requirement for cyclophilin (58–
61). This could suggest that hTE belongs to a larger family of
Nef-interacting proteins or that other Nef-interacting proteins
use a domain similar to that found in hTE to interact with Nef,
but we have no evidence for this.
The above data suggest a possible role for hTE in Nef-medi-
ated CD4 down-regulation. However, although there is a strik-
ing correlation between the ability of NL4–3 Nef to interact
with hTE and its ability to down-regulate CD4, we also provide
evidence for Nef-induced CD4 down-regulation in the absence
of hTE binding. For example, SF2 Nef did not associate with
hTE either in vitro or by immunofluorescence colocalization.
Yet SF2 Nef does down-regulate CD4 in human cell lines (42),
and its ability to down-regulate CD4 is also affected by muta-
tions at Asp123 (Table I), suggesting that this region of Nef may
be needed for CD4 down-regulation in absence of hTE binding.
Moreover, even NL4–3 D108E Nef, which has a low affinity for
hTE, had near wild-type CD4 down-regulation activity. Lastly,
the mutant, D123G NL4–3 Nef, which does not bind to hTE in
our in vitro assays (yeast two-hybrid or GST pull-down), asso-
ciated with Nef in NIH 3T3 cells (Fig. 8I) yet does not down-
regulate CD4 (although it may be argued that the D123G
Nef/hTE interaction involves only the N-terminal part of Nef
(Fig. 6A) and not the core region of Nef and therefore may be
unable to promote CD4 down-regulation). Therefore, although
the interaction of Nef with hTE appears to be quite strong (Fig.
1A) and may involve complex interactions (Fig. 6A), the sim-
plest explanation of our data, at this time, is that hTE is not
critical for Nef-induced down-regulation.
Whatever its biological function, the Nef/hTE association has
been a useful tool to identify a region on Nef critical for CD4
and MHC class I down-regulation. Because mutations in a
neighboring region of Nef, Pro72 and Pro75, are critical for many
of the other functions of Nef (23, 24, 47, 48), these residues
define a conserved region on Nef that is a keystone to almost all
of the functions of Nef. Therefore, a more detailed understand-
ing of the Nef/hTE interaction could be useful in understanding
how a high affinity interaction with Nef is made and in the
design of small molecule Nef inhibitors.
Acknowledgments—We thank members of the Baltimore lab for help-
ful discussions and Bruce Walker, Richard Benarous, Joseph Budman,
Sandra L. Hofmann, Merilyn D. Resh, Chi-Hon Lee, and Richard Cook
for reagents and help on aspects of this project.
REFERENCES
1. Saksela, K. (1997) Front. Biosci. 2, 606–618
2. Trono, D. (1995) Cell 82, 189–192
3. Cullen, B. R. (1994) Virology 205, 1–6
4. Kestler, H. W. d., Ringler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel,
M. D., and Desrosiers, R. C. (1991) Cell 65, 651–662
5. Salvi, R., Garbuglia, A. R., Di Caro, A., Pulciani, S., Montella, F., and
Benedetto, A. (1998) J. Virol. 72, 3646–3657
6. Deacon, N. J., Tsykin, A., Solomon, A., Smith, K., Ludford-Menting, M.,
Hooker, D. J., McPhee, D. A., Greenway, A. L., Ellett, A., Chatfield, C.,
Lawson, V. A., Crowe, S., Maerz, A., Sonza, S., Learmont, J., Sullivan, J. S.,
Cunningham, A., Dwyer, D., Dowton, D., and Mills, J. (1995) Science 270,
988–991
7. Kirchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, J. L., and Desrosiers,
R. C. (1995) N. Engl. J. Med. 332, 228–232
8. Miller, M. D., Warmerdam, M. T., Gaston, I., Greene, W. C., and Feinberg,
M. B. (1994) J. Exp. Med. 179, 101–113
9. Spina, C. A., Kwoh, T. J., Chowers, M. Y., Guatelli, J. C., and Richman, D. D.
(1994) J. Exp. Med. 179, 115–123
10. Swingler, S., Mann, A., Jacque, J., Brichacek, B., Sasseville, V. G., Williams,
K., Lackner, A. A., Janoff, E. N., Wang, R., Fisher, D., and Stevenson, M.
(1999) Nat. Med. 5, 997–103
11. Iafrate, A. J., Bronson, S., and Skowronski, J. (1997) EMBO J. 16, 673–684
12. Graziani, A., Galimi, F., Medico, E., Cottone, E., Gramaglia, D., Boccaccio, C.,
and Comoglio, P. M. (1996) J. Biol. Chem. 271, 6590–6593
13. Skowronski, J., Parks, D., and Mariani, R. (1993) EMBO J. 12, 703–713
14. Garcia, J. V., and Miller, A. D. (1991) Nature 350, 508–511
15. Lama, J., Mangasarian, A., and Trono, D. (1999) Curr. Biol. 9, 622–631
16. Ross, T. M., Oran, A. E., and Cullen, B. R. (1999) Curr. Biol. 9, 613–621
17. Cohen, G. B., Gandhi, R. T., Davis, D. M., Mandelboim, O., Chen, B. K.,
Strominger, J. L., and Baltimore, D. (1999) Immunity 10, 661–671
18. Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D., and Baltimore, D.
(1998) Nature 391, 397–401
19. Le Gall, S., Erdtmann, L., Benichou, S., Berlioz-Torrent, C., Liu, L., Benarous,
R., Heard, J. M., and Schwartz, O. (1998) Immunity 8, 483–495
20. Schwartz, O., Marechal, V., Le Gall, S., Lemonnier, F., and Heard, J. M. (1996)
Nat. Med. 2, 338–342
21. Biggs, T. E., Cooke, S. J., Barton, C. H., Harris, M. P., Saksela, K., and Mann,
D. A. (1999) J. Mol. Biol. 290, 21–35
22. Briggs, S. D., Sharkey, M., Stevenson, M., and Smithgall, T. E. (1997) J. Biol.
Chem. 272, 17899–17902
23. Goldsmith, M. A., Warmerdam, M. T., Atchison, R. E., Miller, M. D., and
Greene, W. C. (1995) J. Virol. 69, 4112–4121
24. Saksela, K., Cheng, G., and Baltimore, D. (1995) EMBO J. 14, 484–491
25. Lock, M., Greenberg, M. E., Iafrate, A. J., Swigut, T., Muench, J., Kirchhoff, F.,
Shohdy, N., and Skowronski, J. (1999) EMBO J. 18, 2722–2733
26. Piguet, V., Gu, F., Foti, M., Demaurex, N., Gruenberg, J., Carpentier, J. L., and
Trono, D. (1999) Cell 97, 63–73
27. Piguet, V., Chen, Y. L., Mangasarian, A., Foti, M., Carpentier, J. L., and Trono,
D. (1998) EMBO J. 17, 2472–2481
28. Greenberg, M. E., Bronson, S., Lock, M., Neumann, M., Pavlakis, G. N., and
Skowronski, J. (1997) EMBO J. 16, 6964–6976
29. Benichou, S., Bomsel, M., Bodeus, M., Durand, H., Doute, M., Letourneur, F.,
Camonis, J., and Benarous, R. (1994) J. Biol. Chem. 269, 30073–30076
30. Trono, D., and Wang, J. K. (1997) Chem. Biol. 4, 13–15
31. Sawai, E. T., Baur, A., Struble, H., Peterlin, B. M., Levy, J. A., and Cheng-
Mayer, C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1539–1543
32. Lu, X., Yu, H., Liu, S. H., Brodsky, F. M., and Peterlin, B. M. (1998) Immunity
8, 647–656
33. Liu, L. X., Margottin, F., Le Gall, S., Schwartz, O., Selig, L., Benarous, R., and
Benichou, S. (1997) J. Biol. Chem. 272, 13779–13785
34. Watanabe, H., Shiratori, T., Shoji, H., Miyatake, S., Okazaki, Y., Ikuta, K.,
Sato, T., and Saito, T. (1997) Biochem. Biophys. Res. Commun. 238,
234–239
35. Naggert, J., Narasimhan, M. L., DeVeaux, L., Cho, H., Randhawa, Z. I.,
Cronan, J. E., Jr., Green, B. N., and Smith, S. (1991) J. Biol. Chem. 266,
11044–11050
36. Morgenstern, J. P., and Land, H. (1990) Nucleic Acids Res. 18, 3587–3596
37. Smith, S. (1981) Methods Enzymol. 71, 181–188
38. Smith, S. (1981) Methods Enzymol. 71, 188–200
39. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993) Proc. Natl.
Acad. Sci. U. S. A. 90, 8392–8396
40. Chen, B. K., Gandhi, R. T., and Baltimore, D. (1996) J. Virol. 70, 6044–6053
41. Kimpton, J., and Emerman, M. (1992) J. Virol. 66, 2232–2239
42. Anderson, S., Shugars, D. C., Swanstrom, R., and Garcia, J. V. (1993) J. Virol.
67, 4923–4931
43. Naggert, J., Witkowski, A., Wessa, B., and Smith, S. (1991) Biochem. J. 273,
787–790
44. Grzesiek, S., Stahl, S. J., Wingfield, P. T., and Bax, A. (1996) Biochemistry 35,
10256–10261
45. Grzesiek, S., Bax, A., Hu, J. S., Kaufman, J., Palmer, I., Stahl, S. J., Tjandra,
N., and Wingfield, P. T. (1997) Protein Sci. 6, 1248–1263
46. Lee, C. H., Saksela, K., Mirza, U. A., Chait, B. T., and Kuriyan, J. (1996) Cell
85, 931–942
47. Mangasarian, A., Piguet, V., Wang, J. K., Chen, Y. L., and Trono, D. (1999)
J. Virol. 73, 1964–1973
48. Greenberg, M. E., Iafrate, A. J., and Skowronski, J. (1998) EMBO J. 17,
2777–2789
49. Luo, T., and Garcia, J. V. (1996) J. Virol. 70, 6493–6496
50. Miura, S., Kasuya-Arai, I., Mori, H., Miyazawa, S., Osumi, T., Hashimoto, T.,
and Fujiki, Y. (1992) J. Biol. Chem. 267, 14405–14411
51. Wiemer, E. A., Wenzel, T., Deerinck, T. J., Ellisman, M. H., and Subramani, S.
(1997) J. Cell Biol. 136, 71–80
52. Jones, J. M., Nau, K., Geraghty, M. T., Erdmann, R., and Gould, S. J. (1999)
J. Biol. Chem. 274, 9216–9223
53. Berge, R. K., Slinde, E., and Farstad, M. (1980) FEBS Lett. 109, 194–196
54. Wilcke, M., and Alexson, S. E. (1994) Eur. J. Biochem. 222, 803–811
55. Crise, B., and Rose, J. K. (1992) J. Biol. Chem. 267, 13593–13597
56. Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H.,
Crompton, A., Chan, A. C., Anderson, J. M., and Cantley, L. C. (1997)
Science 275, 73–77
57. Moore, J. P., Trkola, A., and Dragic, T. (1997) Curr. Opin. Immunol. 9, 551–562
58. Colgan, J., Yuan, H. E., Franke, E. K., and Luban, J. (1996) J. Virol. 70,
4299–4310
59. Thali, M., Bukovsky, A., Kondo, E., Rosenwirth, B., Walsh, C. T., Sodroski, J.,
and Gottlinger, H. G. (1994) Nature 372, 363–365
60. Caccavelli, L., Feron, F., Morange, I., Rouer, E., Benarous, R., Dewailly, D.,
Jaquet, P., Kordon, C., and Enjalbert, A. (1994) Neuroendocrinology 60,
314–322
61. Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V., and Goff, S. P. (1993)
Cell 73, 1067–1078
hTE Binding Site on Nef 23105
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Decem
ber 29, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
